Novartis acquires neuromuscular gene therapy firm AveXis for $8.7bn
Novartis AG agreed to acquire public gene therapy company AveXis Inc. (focused on rare neuromuscular diseases) for $8.7bn. The deal has an enterprise value of $8.4bn.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.